| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
Fifth Side Letter — Closing under Series B Preferred Purchase Agreement |
| 05 Nov 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 02 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Certain personal information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K. The omitted information is indicated by “[***]” |
| 29 Oct 2026 |
8-K: Other Events
Valion Bio Announces Positive Safety Results from U.S. Government-Funded Entolimod Study, Paving Way for Therapeutic Efficacy Evaluation |
| 27 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
Re: Fourth Side Letter — Closing under Series B Preferred Purchase Agreement |
| 26 Oct 2026 |
8-K: Other Events
Unsolicited Interest Reinforces Velocity's Strategic Value as Valion Bio Evaluates Opportunities to Advance Entolimod |
| 22 Oct 2026 |
8-K: Other Events
Interim CEO Dean Zikria’s initial review prioritizes Entolimod and pipeline advancement, commercialization of Velocity Bioworks, and strategic opportunities to maximize the value of the Company’s integrated capabilities |
| 15 Oct 2026 |
8-K: Other Events
Velocity Bioworks successfully completes initial evaluation of LarmorBio’s BioScan-NMR™ platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess monitoring of cell size, density, vi... |
| 14 Oct 2026 |
8-K: Other Events
With Section 232 Tariffs Reshaping Biotech, Valion Bio’s Velocity Bioworks Capitalizes on Domestic CDMO Surge |
| 08 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
Third Side Letter — Closing under Series B Preferred Purchase Agreement |
| 06 Oct 2026 |
8-K: Other Events
Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government funding, FDA designations, human safety data and wholly owned U.S. manufacturing |
| 01 Oct 2026 |
8-K: Other Events
Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity |
| 23 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This CONSULTING AGREEMENT (this “Agreement”) with an effective date of September 22, 2026 (“Effective Date”) is made by and between Valion Bio, Inc. (the “Company” or “Valion”), and Dean Zikria (“Consultant”). |
| 01 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors. |
| 27 Aug 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
SAN ANTONIO, TX – August 27, 2026 – Valion Bio, Inc. (Nasdaq: VBIO) (“Valion Bio” or the “Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company’s issued and outstanding shares of ... |
| 17 Aug 2026 |
8-K: Unregistered Sales of Equity Securities; Departure/Election of Directors or Officers; Compensation +2 more
This ROYALTY AGREEMENT (this “Agreement”), dated as of August 17, 2026, is by and between Velocity Bioworks, Inc., a Delaware corporation (“VBI”), Valion Bio, Inc., a Delaware corporation (the “Parent,” and together with VBI, the “Payor ... |
| 06 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
On July 31, 2026, the Company issued an aggregate of 1,287.8685 shares of Series A Preferred Stock (“Milestone Shares”), as consideration for the Milestone Payment (as discussed in more detail in Item 8.01 below), to Statera and Avenue V... |
| 14 Jul 2026 |
8-K: Regulation FD Disclosure
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion |
| 18 Jun 2026 |
8-K: Unregistered Sales of Equity Securities; Other Events
As previously announced, on April 29, 2025, Valion Bio, Inc. (formerly known as Tivic Health Systems, Inc.) (the “Company”) entered into a Securities Purchase Agreement (as subsequent assigned and amended, the “Purchase Agreement”) with ... |
| 03 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
WHEREAS, the Board of Directors and stockholders of Valion Bio, Inc. (formerly known as Tivic Health Systems, Inc.) (the “Company”) have each adopted and approved the Valion Bio, Inc. Amended and Restated 2021 Equity Incentive Plan, as a... |
Loading...